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Prospective trial of preoperative gefitinib to correlate response 
with EGFR exon 19 and 21 mutations and to select patients for 
adjuvant gefitinib
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Background: Induction therapy provides a unique opportunity to 
evaluate therapies in patients with NSCLC to personalize care and 
facilitate drug research. We designed this 50 patient prospective trial 
to correlate response with geﬁtinib measured by CT with mutations in 
EGFR exons 19 and 21 and to simultaneously assess the agent’s ability 
to induce regressions preoperatively in persons with NSCLC. To do 
this, we enriched the group studied to select individuals with tumors 
more likely to harbor EGFR mutations. 
Methods: Patients with stage I or II NSCLC have a baseline chest CT 
and a core-needle biopsy to detect EGFR mutations. All participants 
smoked cigarettes 10 pack years and/or had tumors with bronchioloal-
veolar features. All receive geﬁtinib 250 mg daily. After 21 days, the 
CT is repeated and resection follows. Surgical specimens are again 
assayed for EGFR mutations and KRAS mutations. Patients with muta-
tion and/or 25% regression (WHO) are given geﬁtinib for 2 years. 
Results: Among 34 patients enrolled to date, EGFR mutations were 
detected in 12(35%); results were identical in 17/17 matched core 
biopsy and resection specimens. Thirteen (38%) had a 25% bidimen-
sional tumor reduction after 21 days. The mutation rate was 77% in 
responding patients and 10% in patients without response, P=0.0001 
for the primary study endpoint. The regression observed after 21 days 
of geﬁtinib and the correlation with EGFR mutation for each patient is 
shown in the ﬁgure. 0/3 patients with KRAS mutations had response or 
EGFR mutation. No increase in perioperative complications occurred. 
15 patients received geﬁtinib postoperatively. 
Conclusions: In this ongoing trial, 1) The rate of EGFR mutation 
was signiﬁcantly higher in patients with response to geﬁtinib. 2) Our 
enrichment strategy resulted in the detection of three times the expected 
number of EGFR mutations in USA patients with NSCLC. 3) Geﬁtinib 
sensitivity can be assessed by CT in 21 days. 4) Results of mutation 
detection were identical in pre- and post-treatment specimens. Support: 
CA05826, CA113653.
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Background: ERCC6 (alternate name CSB) is involved in both 
transcription coupled and base excision DNA repair, and the ERCC6 C-
6530>G SNP is involved in gene regulation. Different levels of ERCC6 
mRNA expression have been observed in cells according to ERCC6 
- 6530 genotype. 
Methods: We investigated the ERCC6 C-6530>G SNP in 309 stage IV 
NSCLC p treated with doc/cis (196 p) and gem/cis (113 p). DNA was 
extracted from peripheral lymphocytes and Taqman assay was used for 
SNP typing. 
Results: Distribution of ERCC6 genotypes was: CC 113 p (36.6%); 
CG 157 p (50.8%); GG 39 p (12.6%). No differences in genotype were 
observed according to age, gender, performance status (PS), histology, 
chemotherapy regimen or second-line treatment. Overall time to pro-
gression (TTP) was 5.4 months (m) and median survival (MS) 9.9 m. 
No differences in TTP or MS were observed according to ERCC6 SNP 
types. However, when p were broken down by chemotherapy regimen, 
TTP was 7 m for 31 CC p treated with gem/cis and 5.4 m for 71 CC p 
treated with doc/cis (P=0.04) (Table). MS was longer for CC p treated 
with gem/cis (11 m) than for CC p treated with doc/cis (8.9 m) (P=0.46). 
Differences were also observed in p with PS 0 and in younger p.
Conclusions: ERCC6 C-6530>G SNP may confer differential sensitiv-
ity to gem or doc in combination with cis. We hypothesize that ERCC6 
6350 CC is a surrogate of ERCC6 transcript, where lower ERCC6 
expression levels may increase the activity of gem/cis in comparison to 
doc/cis.
ERCC6 N TTP 95% CI P
CC    0.04
Doc/Cis 75 5.4 m 3.1 - 7.7  
Gem/cis 31 7 m 2.5 - 11.4  
GG    0.90
Doc/cis 22 5.9 m 4.3 - 7.5  
Gem/cis 17 4 m 0.4 - 7.6  
CG    0.95
Doc/cis 99 5.2 m 4 - 6.4  
Gem/cis 56 6 m 4.8 - 7.2  
